SEC Filing Summary: Salarius Pharmaceuticals, Inc. (SLRX)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Salarius Pharmaceuticals, Inc. on October 14, 2025, covering events occurring on October 10, 2025. The registrant is a biopharmaceutical company listed on The Nasdaq Capital Market under the symbol SLRX. The filing addresses the company's compliance status with Nasdaq listing requirements.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stockholders' equity rather than operational financial performance.
Material Changes
- Regulatory Compliance: On October 10, 2025, the Nasdaq Hearings Panel notified Salarius that it has regained compliance with the minimum stockholders' equity requirement (Nasdaq Listing Rule 5550(b)(1)).
- Monitoring Status: The company is subject to a Mandatory Panel Monitor for a period of one year from October 10, 2025.
Outlook, Risks, and Contingencies
Delisting Risk: If Salarius falls out of compliance with the Equity Standard again within the one-year monitoring period, the company will not be permitted to submit a plan of compliance or receive additional cure periods. Instead, the Nasdaq Listing Qualifications Staff will issue a delisting determination letter, at which point the company may request a hearing.
Management Commentary: On October 13, 2025, the company issued a press release confirming the regained compliance status.
Investor Verification Checklist
- Verify the current stockholders' equity balance to ensure it remains above the Nasdaq minimum threshold.
- Monitor future filings for any indications of renewed non-compliance during the one-year Mandatory Panel Monitor period.
- Review the press release filed as Exhibit 99.1 for additional details on the compliance restoration.
- Confirm the company's ongoing ability to meet other Nasdaq listing standards beyond the equity requirement.